By UNIVERSITY OF CALIFORNIA – LOS ANGELES HEALTH SCIENCES: Click through for the full post…
Research from UCLA demonstrated that a combination therapy of naltrexone and bupropion effectively reduced methamphetamine use in trial participants over 12 weeks, suggesting the potential of pharmacological interventions in addressing rising overdose rates.
A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment, according to the results of UCLA-led research.
Participants in the ADAPT-2 clinical trial who received a combination of injectable naltrexone plus extended-release oral bupropion (NTX+BUPN) had a 27% increase in methamphetamine-negative urine tests, indicating reduced usage. By contrast, the placebo group had an 11% increase in negative tests.
The study will be published in the peer-reviewed journal Addiction.